Effect of carvedilol on premature ventricular complexes originating from the ventricular outflow tract

[1]  B. Lerman.  Mechanism, diagnosis, and treatment of outflow tract tachycardia , 2015, Nature Reviews Cardiology.

[2]  Douglas P. Zipes,et al.  Clinical Arrhythmology and Electrophysiology: A Companion to Braunwald's Heart Disease , 2012 .

[3]  H. Duff,et al.  Carvedilol and its new analogs suppress arrhythmogenic store overload–induced Ca2+ release , 2011, Nature Medicine.

[4]  W. Remme.  Which Beta-Blocker is Most Effective in Heart Failure? , 2010, Cardiovascular Drugs and Therapy.

[5]  Huihui Kong,et al.  Enhanced Store Overload–Induced Ca2+ Release and Channel Sensitivity to Luminal Ca2+ Activation Are Common Defects of RyR2 Mutations Linked to Ventricular Tachycardia and Sudden Death , 2005, Circulation research.

[6]  J. McMurray,et al.  Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. , 2005, Journal of the American College of Cardiology.

[7]  H. Krumholz,et al.  Adverse effects of beta-blocker therapy for patients with heart failure: a quantitative overview of randomized trials. , 2004, Archives of internal medicine.

[8]  Heping Cheng,et al.  RyR2 mutations linked to ventricular tachycardia and sudden death reduce the threshold for store-overload-induced Ca2+ release (SOICR). , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[9]  C. Coffey,et al.  Adverse effects of -blocker therapy for patients with heart failure: A quantitative overview of ran , 2004 .

[10]  P. Poole‐Wilson,et al.  Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial , 2003, The Lancet.

[11]  H. Girault,et al.  Structure-Lipophilicity Relationships of Neutral and Protonated β-Blockers, Part I, Intra- and Intermolecular Effects in Isotropic Solvent Systems , 1999 .

[12]  G. A. West,et al.  Adenosine-sensitive ventricular tachycardia: evidence suggesting cyclic AMP-mediated triggered activity. , 1986, Circulation.

[13]  M. Gheorghiade,et al.  Carvedilol: beta-blockade and beyond. , 2004, Reviews in cardiovascular medicine.

[14]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[15]  A. Yao,et al.  Characteristic effects of alpha1-beta1,2-adrenergic blocking agent, carvedilol, on [Ca2+]i in ventricular myocytes compared with those of timolol and atenolol. , 2003, Circulation journal : official journal of the Japanese Circulation Society.

[16]  H. Spahn‐Langguth,et al.  Carvedilol Stereopharmacokinetics in Rats: Affinities to Blood Constituents and Tissues , 1993, Archiv der Pharmazie.

[17]  M. Fujimaki.  Stereoselective disposition and tissue distribution of carvedilol enantiomers in rats. , 1992, Chirality.